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ANALYSIS OF TWO MUTATIONS IN
THE MTHFR GENE ASSOCIATED
WITH MILD HYPERHOMOCYSTEIN-
AEMIA - HETEROGENEOUS
DISTRIBUTION IN THE SOUTH
AFRICAN POPULATION
Charlotte L Scholtz, Hein JOdendaal, Rochelle Thiart, Lynzie
Loubser, Renate Hillermann, Rhena Delport, W JHayward
Vermaak, Maritha JKotze
Objective. The frequencies of mutations 677C--+T and
1298A--+C in the methylenetetrahydrofolate reductase
(MTHFR) gene, previously shown to be associated with
decreased enzyme activity that may lead to
hyperhomocysteinaemia and consequently increased risk of
cardiovascular disease (CVD), were determined in the
South African population.
Methods. HinfI (677C--+T) and MboII (1298A--+C) restriction
enzyme analyses were performed on amplified DNA
samples of 76 white, 73 coloured and 60 black subjects.
Results. The mutant alleles of mutations 677C--+T and
1298A--+C were more common in the white (allele
frequencies 0.36 and 0.37, respectively) than in the black
population (0.04 and 0.09), while intermediate frequencies
were detected ill the coloured population (0.18 and 0.30).
Homozygosity for mutation 677C --+T was not detected in
the black cohort, while this genotype was detected in 1
coloured (1.4%) and 8white (10.5%) subjects. In the black
population, 5% of the 60 subjects analysed were
homozygous for mutation 1298A--+C, compared with
approximately 12% -in both the white and coloured
populations.
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ConcIusians, Since hyperhomocysteinaemia is a risk factor for
premature CVD, the heterogeneous distribution of the
677C~Tand 1298A~mutations across ethnic groups may
partly explain ethnic differences in heart disease risk through
decreased enzyme activity and hence increased homocysteine
levels,
S Afr Med J2002; 92: 464-467.
Cardiovascular disease (CVD) is a multifactorial condition
caused by an interaction of genetic and environmental factors,
In addition to well-known risk factors including low high-
density lipoprotein (HDL) and raised low-density lipoprotein
(LDL) cholesterol, triglycerides, fibrinogen and lipoprotein(a)
(Lp(a», elevated plasma homocysteine concentration has
consistently been identified as a risk factor for the development
of CVD,I In 1995 Frosst et aP identified a C to T base change at
nucleotide position 677 in the methylenetetrahydrofolate
reductase (MTHFR) gene, which is responsible for increased
thermolability of the enzyme, causing mild
hyperhomocysteinaemia, Although various studies have
demonstrated a positive association between CVD and this
polymorphism, lack of association has also been reported, _
indicating that environmental interaction and the genetic
background of the study population are important
determinants of risk imposed by mutation 677C~p-5 More
recently, a second common mutation, 1298A~C, resulting in
decreased MTHFR activity, has been identified in the MTHFR
gene.' This sequence variant is not associated with elevated
plasma homocysteine levels or a lower plasma folate
concentration, although combined heterozygosity for both
mutations results in increased thermolability of the enzyme
and elevated homocysteine levels. Van der Put et aI' indicated
that mutation 1298A~Cmay be an additional risk factor for
neural tube defects (NTDs), but its possible role in CVD has
not yet been defined.
Since the public health relevance of MTHFR mutations
causing hyperhomocysteinaemia would largely depend on the
frequency of disease-related mutations within a population, we
analysed the 677C~Tand 1298A~CMTHFR mutations in the
South African population. We attempted to determine whether
the distribution of MTHFR mutations among ethnic groups
might be associated, at least in part, ",,'ith ethnic differences in
risk of CVD. The pattern of CVD differs in various population
groups in South Africa,''' and this phenomenon has been
attributed largely to differences in lifestyle and diet.7.' During
recent years several studies have contributed to a growing
awareness of the significant role of genetic factors predisposing
an individual to different forms of heart disease, including the
demonstration that three founder-related low-density
lipoprotein receptor (LDLR) gene mutations are responsible for
the high prevalence (l/70) of familial hypercholesterolaemia
(FH) in the South African Afrikaner population. la These
mutations shown to be responsible for the disease in
approximately 90% of affected Afrikaners were absent in the
black population, while detected in 10 - 20% of coloured FH
patients. !I The detection of multiple founder-type LDLR gene
mutations originating from European populations provided
direct genetic evidence that Caucasoid admixture contributes
Significantly to the apparently high prevalence (> 1/500) of FH
in the South African coloured population. This finding has
demonstrated the potential consequences of recent admixture
in populations with different disease risks, a phenomenon that
may also be of relevance to the present study of MTHFR
mutations in the general South African population.
MATERIALS AND METHODS
Subjects
Blood samples of 209 individuals from three different ethnic
groups in South Africa (Table 1) were collected after obtaining
informed consent: 60 Xhosa, Pedi and Zulu individuals (black
population), 73 of mixed ancestry (coloured population) and 76
Caucasians (white population). These included healthy blood
donors, farm workers and laboratory personnel. In this study
'white' or 'Afrikaner' refers to an individual of European
descent, mainly Dutch, French, German and British origin;
'coloured' refers to an individual of mixed ancestry, including
Khoisan, African Negro, Madagascar, Javanese and European
origin; and 'black' refers to South Africans of central African
descent.
Mutation detection
Genomic DNA was extracted from whole blood according to
the method of Miller et aI.,U and amplified by the polymerase
chain reaction (PCR) using previously described
oligonucleotides.'-' Amplified products were digested with
HinfI and MboII restriction enzymes for detection of mutations
677C~Tand 1298A~C, respectively. HinfI digested products
were electrophoresed on a 12% polyacrylamide gel and MboII
digestions on a 20% polyacrylamide gel. Bands were visualised
under ultraviolet light following ethidium bromide staining.
Statistical analysis
Chi-square values were calculated and their significance levels
determined by two-way contingency tables. P-values of < 0.05
were regarded as statistically significant. Em
RESULTS AND DISCUSSION
The frequencies of the 677C~Tand 1298A~CMTHFR gene
mutations were determined in the diverse South African
population in order to evaluate their potential in predicting
___________-o;====~.~~===.....,._:-__=.,_._._--_~==~=__ .. _
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Table I. Comparison of genotype distribution and allele frequencies of two MTHFR gene mutations in three ethnic groups in South Africa
White" Colouredt Black!:
M1HFR Genotype/ (N= 76) (N= 73) (N = 60)
mutations allele N % N % N %
677C---)T CC 30 39 47 65 55 92
er 38 50 25 34 5 8
IT 8 11 1 2 0 0
Allele C 98 64 119 82 113 96
Frequency T 54 36 27 18 5 4
1298A---)C AA 29 38 40 55 52 87
AC 38 50 24 33 5 8
CC 9 12 9 12 3 5
Allele A 96 63 93 70 109 91
Frequency C 56 37 39 30 11 9
Genotype distributions and allele frequencies differed significantly:
• White v. coloured: P < 0.03 (677 C4T mutation only).
tColoured v. Black: P < 0.004 (both mutations).
lBIack v. white: P < 0.0001 (both mutations).
CVD risk in different ethnic groups. The results obtained
following HinfF and MboIl6 restriction enzyme analysis in the
unselected white, black and coloured populations are shown in
Table 1. Statistically significant differences for the two
mutations were observed among the different South African
population groups, with regard to both genotype distribution
and allele frequencies (P < 0.01). However, no significant
difference could be detected between whites and coloureds for
mutation 1298A---)C. The mutant alleles of mutations 677C---)T
and 1298A---)C were more common in the white (allele
frequencies 0.36 and 0.37, respectively) than in the black
population (0.04 and 0.09), while intermediate frequencies were
detected in the coloured population (0.18 and 0.30).
Homozygosity for mutation 677C~Twas not detected in black
subjects, consistent with the findings of Ubbink et al.," who
indicated that this genotype does not constitute a genetic risk
factor for NTDs in South African blacks. These results are in
accordance with the lower homocysteine levels reported
previously in this population compared with Caucasians."'!S
Three of 60 black individuals analysed (5%) were homozygous
for mutation 1298A~C.The frequency of the mutant allele of
mutation 677C---)T among whites and blacks was similar to
those previously reported for the different ethnic groupS.16
Mutation 1298A~Chas not yet been studied extensively, but
the frequency of the C-allele in South African Caucasians (0.37)
was similar to that, in control individuals (0.33) previously
studied in the Netherlands,6
The heterogeneous distribution of two MTHFR gene
mutations among different ethnic groups in South Africa may
be one of several factors underlying the differences observed in
the risk of heart disease, This may particularly be the case for
the extensively studied 677C~T mutation, which can be
considered an established risk factor for CVDP The study
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participants were recruited from the general South African
population, where heart attack deaths in the coloured
population are less common than in the white population but
more prevalent than in the black population,17 The intermediate
frequency of the two common MTHFR mutations observed in
the coloured population is in accordance with previous
findings indicating an increased manifestation of coronary
heart disease (CHD) in this population,18 possibly as a
consequence of Caucasoid admixture,"
While various studies have demonstrated that mild
hyperhomocysteinaemia is associated with CHD, no conclusive
reports have yet been published.·on its possible role in the
development of CHD in PH patients, In a pilot study
(performed in the Western Cape), a significant association was
found between homozygosity for mutation 677C~Tand CHD
in patients with the common Afrikaner founder mutation
D206E (P = 0,027), suggesting that the 677-TI genotype is
associated with a high CHD risk in these PH patients,19 This
finding could, however, not be replicated in an extended group
of Afrikaner PH heterozygotes' from a different geographical
region (Gauteng) in South Africa (M J Kotze, C L Scholtz, F J
Raal - unpublished data). The contradictory findings in
patients with similar genetic backgrounds may be suggestive of
environmental differences such as vitamin intake, and/or may
reflect differences in selection criteria used at different lipid
clinics. The allele frequency of mutation 1298A~Cwas not
significantly higher in the CHD-positive group compared with
the CHD-negative group, or with combined genotypes for both
mutations (MJ Kotze, CL Scholtz and FJ Raal - unpublished
results), The 677C~Tmutation occurred at a significantly
lower frequency (P < 0,05) in 102 molecularly characterised
Afrikaner PH index cases (above the age of 25 years) compared
with control individuals drawn from the same population,
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which raises the possibility that the MTHFR gene represents a
modifier locus for FH.
It has also previously been noted that the effect of mutation
677C~Ton homocysteine concentration may differ in separate
studies as a result of a variable intake of folate, since this
mutation leads to elevated plasma homocysteine
concentrations only in individuals with a low folate status.'"
Biochemical analysis has indeed indicated higher folate levels
in 20 FH heterozygotes 08.9 ± 19.4 nmol/1) (from the Afrikaner
group where association between CHD and the MTHFR
mutation could not be detected) compared with 20 controls
04.4 ± 6.2 nmol/1).21 The significantly lower plasma
homocysteine concentrations detected in these FH patients may
be related to a healthier lifestyle/diet in families known to be
affected with FH. In light of recent reports on possible
beneficial effects of vitamin supplementation in the prevention
of CVD,:'2 dietary considerations should form an important
aspect of future studies on the role of MTHFR mutations in
CHD risk in FH.
Although it may be too laborious and expensive to include
dietary information and perform all the relevant biochemical
tests for such a study, conclusive results would probably only
be obtained in the absence of possible confounding factors. A
recent study performed by Tonstad et aF3 in children with FH
addressed this issue. These authors convincingly demonstrated
a moderately elevated plasma homocysteine level associated
with a parental history of CVD, and demonstrated that
homozygosity for mutation 677C~Toccurs more frequently in
FH children with than in a group without a parental history of
CVD.
The wide spectrum of phenotypic variability observed in FH
patients sharing the same defective allele"4-" suggests that other
important predictors of CHD risk in FH remain to be
identified. A population-based approach would only reveal
major additive factors, since different CHD risk factors could
be present in different FH families. The key to unravelling the
various factors likely to be involved in the development of
CHD in FH heterozygotes are probably, as suggested
previously,:" to be found in families where the clinical
expression of FH varies among relatives.
In summary, we have demonstrated a heterogeneous
distribution of MTHFR genotypes among different ethnic
groups, which may partly explain differences l ' in the risk for
heart disease in the genetically distinct populations of South
Africa. Although it is possible that deleterious MTHFR
genotypes \'\ill only emerge as a risk factor for CVD in
populations with a low folate status, it appears appropriate to
screen all patients with a history of premature atherosclerosis
for established risk factors, including elevated homocysteine
levels, which can be normalised. Assessment of genetic risk
factors in families with a history of CVD, and timely
implementation of appropriate measures before the onset of
disease, may represent an important strategy towards
prevention of CVD predicted to become the leading cause of
death in developing countries by the year 2020.
This study was supported by the Universities of Stellenbosch
and Pretoria, the South African Medical Research Council and the
Technology and Human Resources for Industry Programme. CL
Scholtz received a student bursary from the Harry Crossley
Foundation. R Hillermann is a recipient of a Stellenbosch
University postdoctoral fellowship.
References
1. McCully KS. Homocysteine and vascular disease. Nat Med 1996; 2: 386-389.
2. Frosst P, Slam HJ. Milos R, et al. A candidate genetic risk factor for vascular disease: a
common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-113.
3. Kluijtmans LA}, Van den Heuvel LPWJ. Boers CHJ. et a1. Molecular genetic analysis in mild
hyperhomocysteinaemia: a common mutation in the methylenetetrahydrofolate reductase
gene is a genetic risk factor for cardiovascular disease. Am / Hum Gene11996; 58: 35-41.
4. Abbate R, Sardi I, Pepe C, et al. The high prevalence of thermolabile >-'10
methylenetetrahydrofolate reductase (MRHFR) in Italians is not associated to an inaeased
risk for coronary artery disease (CAD). Thromb Htzemost 1998; '79= ""-.7-730.
5. Girelli 0, Frisso 5, Trabetti E, et al. Methylenetetrahydrofolate reductase C677T mutation,
plasma homocysteine, and folate in subjects from northern Italy with or without
angiographically documented severe coronary atherosclerotic disease: evidence for an
important genetic-e.nvironmental interaction. Blood 1998; 91: 4158-4163.
6. Van der Put NMJ, GabreeIs F, Stevens EMB, et at. A second common mutation in the
methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects?
Am JHum G<",t 1998; 6Z, 1044-1051.
7. Walker ARP. Smdies bearing on coronary heart disease in South African populations. 5 AfT
Mro J1973; 47, 85-90.
8. Wyndham CH. Mortality from cardiovascular diseases in various population groups in the
Republic of South Africa. 5 Air Mro J1979; 56, 1023-1030.
9. Trowell H, Painter ,Burkitt D. Aspects of the epidemiology of diverticular disease and
ischaemic heart disease. Am JDig Dis 1974; 1~ 864.
10. Kotze MJ, Langenhoven E, Wamich l, Du Plessis l, Retief AE. The molecular basis and
diagnosis of familial hypercholesterolemia in South African Afrikaners. Ann Hum Genet 1991;
55: 11>-'121.
11. Loubser 0, Marais AD, Kotze Ml, et al. Founder mutations in the lDl receptor gene
contribute significantly to the familial hypereholesterolemia phenotype in the indigenous
South African population of mixed ancestry. Clin Grnet 1999; 55, 340-345.
12. Miller SA. Dykes DD, Polesky HE A simple salting out procedure for extracting DNA from
human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
13. Ubbink JB, Vermaak WJH, Delport R, Van der Merwe A, Becker PJ, Potgieter H. Effective
homocysteine metabolism may protect South African blacks against coronary heart disease.
Am JClin Nutr 1995; 6Z, 802-1lO8.
H. Vermaak WJH, Ubbink lB, Delport R. Becker PJ, Bissbort SH, Vngerer JPJ. Ethnic immunity
to coronary heart disease? Atherosclerosis 1991; 89: 15>-'162-
15. UbbinkJB, Christianson A, Bester Mj, et at Folate status, homocysteine metabolism, and
methylene tetrahydrofolate reductase genotype in rural South African Blacks with a history
of pregnancy complicated by neural tube defects. Mdaholism 1999; 48, 26~274.
16. Franco RF, Anujo AG, Guerreiro JF, ElionJ, Zago MA. Analysis of the 671C-4T mutation of
the methylenetetrahydrofolate reductase gene in different ethnic groups. Thromb Haemost
1998; 7'F. 11~121.
17. Steyn K, Jooste Pl, Lmgenhoven ML, et al. Coronary risk factors in the coloured population
in the Cape Peninsula 5 Air Mal J 1985; 67, 619-625.
18. Steyn K, Rossouw jE, JoubeIt G. The coexistence of major coronary heart disease risk factors
in the coloured population of the Cape Peninsula (CRlSIC study). 5 Afr M'd J1990; 78, 61~.
19. Peeters AV. Analysis of the genetic contribution to the risk of cardiovascular disease in
monogenic hypercholesterolemia. PhD Thesis, University of Stellenbosch, 1997.
20. Kluijtmans LAJ, Kastelein}JP, Lindemans J, et al. Thennolabile methylenetetrahydrofolate
reductase in coronary artery disease. Circulation 1997; %, 2573-2571.
21. Raal FJ, Pilcher GJ, Waisberg R. Buthe1ezi Er, Veller MG, Joffe Br. low-<lensity lipoprotein
cholesterol bulk is the pivotal detenninant of atherosclerosis in familial
hypereholesterolemia. Am JCardioll999; 83, 1330-1333.
22 Tha r. Rather M, Lonn E, Farkouh M, Yusuf S. The antioxidant vitamins and cardiovascular
disease. Ann Intmt Mal 1995; 123, 860-872.
23. Tonstad 5, Refsum H, Ueland PM. Association in plasma total homocysteine and parental
history of cardiovascular disease in children with familial hypereholesterolemia. Circulation
1997; %,1803-1808.
24. Kotze MJ, Davis HI, Bissbort S, Langenhoven E, Brusnicky J, Oosthuizen CJJ. [ntrafamilial
Variability in the clinical expression of familial hypercholesterolemia: importance of risk
factor determination for genetic counselling. Clin Genet 1993; 43: 295-299.
25. Ferrieres J, lambert J, lussier-eacan 5, Davignon J. Coronary artery disease in heterozygous
familiaJ hyperc.holesterolemia patients ""rith the same lDl receptor gene mutation. Circulation
1995; 9Z, 29G-295.
26. Pimstone SN, Sun X-M, Du Souich C, Frohlich JJ, Hayden MR. Soutaf AK Phenotypic
variation in heterozygous familial hypercholesterolemia. Arleriosder Thromb Vase BioI 1998;
18,309-315.
Acupled 8 Dec""ber 200].
mJl
